MenQuadfi

RSS

meningococcal group A, C, W-135 and Y conjugate vaccine

Authorised
This medicine is authorised for use in the European Union.

Overview

MenQuadfi is a vaccine used to protect adults and children from the age of 12 months against invasive meningococcal disease caused by four groups of the Neisseria meningitidis bacteria (group A, C, W, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning).

The vaccine contains substances from the outer coat of N. meningitidis bacteria.

This EPAR was last updated on 01/03/2023

Authorisation details

Product details
Name
MenQuadfi
Agency product number
EMEA/H/C/005084
Active substance
  • Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
  • Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid
International non-proprietary name (INN) or common name
meningococcal group A, C, W-135 and Y conjugate vaccine
Therapeutic area (MeSH)
Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
J07AH08
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Pasteur
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
18/11/2020
Contact address

14 Espace Henry Vallée
69007 Lyon
France

Product information

27/02/2023 MenQuadfi - EMEA/H/C/005084 - N/0021

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

The use of this vaccine should be in accordance with available official recommendations.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating